{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:35:00Z","timestamp":1785454500563,"version":"3.56.0"},"reference-count":38,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2019-0214_s_999_w2aab3b7c23b1b6b1aab1c16b1Aa\">\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Studies evaluating effects of gonadotropin-releasing hormone agonist (GnRHa) on weight and body-mass-index (BMI) in girls with idiopathic central precocious puberty (iCPP) include short-term effects. The aim of this study is to investigate changes in BMI during and 2 years after completion of GnRHa to determine the factors that may impact BMI in girls with iCPP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2019-0214_s_998_w2aab3b7c23b1b6b1aab1c16b2Aa\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Medical files of 138 girls who completed GnRHa were evaluated. All patients had weight and height measurements at the beginning and end of treatment, and 111 patients had anthropometric measurements 2 years after the completion of treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2019-0214_s_997_w2aab3b7c23b1b6b1aab1c16b3Aa\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the beginning, 82 (59.4%) had normal weight (NW), 42 (30.4%) were overweight (OW), and 14 (10.2%) were obese (OB). Analysis of BMI-standard deviation score (SDS) in the whole group showed an overall increase during GnRHa treatment (0.92\u2009\u00b1\u20090.74 vs. 1.20\u2009\u00b1\u20090.51, p\u2009&lt;\u20090.001). Changes in BMI-SDS (\u0394BMI-SDS) during GnRHa differed between NW and OW\/OB (0.45\u2009\u00b1\u20090.31 vs. 0.03\u2009\u00b1\u20090.20, p\u2009&lt;\u20090.001). BMI-SDSs of both groups returned to baseline scores (or initial levels) 2 years after the completion of treatment. Two factors affecting \u0394BMI-SDS in multiple linear regression analyses were baseline BMI and \u0394height-SDS, both correlated negatively with \u0394BMI-SDS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2019-0214_s_996_w2aab3b7c23b1b6b1aab1c16b4Aa\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The present study is one of the studies evaluating BMI change over a long period of time in girls with CPP. Although BMI-SDS increased during GnRHa in NW girls, it was reversible in follow-up after treatment. However, BMI-SDS did not change during and in follow-up in OW\/OB girls. Conserving BMI-SDS in OW\/OB girls may be related to the fact that weight management programs were recommended for these patients. Dietary recommendations should be provided for children with NW who undergo GnRHa, as is the case for OW patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2019-0214","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T09:06:27Z","timestamp":1575536787000},"page":"99-105","source":"Crossref","is-referenced-by-count":33,"title":["Long-term effects of GnRH agonist treatment on body mass index in girls with idiopathic central precocious puberty"],"prefix":"10.1515","volume":"33","author":[{"given":"Dogus","family":"Vuralli","sequence":"first","affiliation":[{"name":"Division of Pediatric Endocrinology, Department of Pediatrics , Hacettepe University Medical School , Ankara , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep Alev","family":"Ozon","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Department of Pediatrics , Hacettepe University Medical School , Ankara , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmas Nazli","family":"Gonc","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Department of Pediatrics , Hacettepe University Medical School , Ankara , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayfer","family":"Alikasifoglu","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Department of Pediatrics , Hacettepe University Medical School , Ankara , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurgun","family":"Kandemir","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Department of Pediatrics , Hacettepe University Medical School , Ankara , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2019,12,5]]},"reference":[{"key":"2021021317253200277_j_jpem-2019-0214_ref_001_w2aab3b7c23b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:e752\u201362.","DOI":"10.1542\/peds.2008-1783"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_002_w2aab3b7c23b1b6b1ab2b1b2Aa","unstructured":"Palmert MR, Mansfield MJ, Crowley Jr WF, Crigler Jr JF, Crawford JD, et al. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab 1999;84:4480\u20138."},{"key":"2021021317253200277_j_jpem-2019-0214_ref_003_w2aab3b7c23b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Feuillan PP, Jones JV, Barnes K, Oerter-Klein K, Cutler Jr GB. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. J Clin Endocrinol Metab 1999;84:44\u20139.","DOI":"10.1210\/jcem.84.1.5409"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_004_w2aab3b7c23b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Chiumello G, Brambilla P, Guarneri MP, Russo G, Manzoni P, et al. Precocious puberty and body composition: effects of GnRH analog treatment. J Pediatr Endocrinol Metabol 2000;13 Suppl 1:791\u20134.","DOI":"10.1515\/JPEM.2000.13.S1.791"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_005_w2aab3b7c23b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Paterson WF, McNeill E, Young D, Donaldson MD. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. Clin Endocrinol 2004;61:626\u201334.","DOI":"10.1111\/j.1365-2265.2004.02146.x"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_006_w2aab3b7c23b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Lee SJ, Yang EM, Seo JY, Kim CJ. Effects of gonadotropin-releasing hormone agonist therapy on body mass index and height in girls with central precocious puberty. Chonnam Med J 2012;48:27\u201331.","DOI":"10.4068\/cmj.2012.48.1.27"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_007_w2aab3b7c23b1b6b1ab2b1b7Aa","unstructured":"Messaaoui A, Massa G, Tenoutasse S, Heinrichs C. [Treatment of central precocious puberty with Gonadotropin-Releasing Hormone agonist (triptorelin) in girls: breast development, skeletal maturation, height and weight evolution during and after treatment]. Rev Med Brux 2005;26:27\u201332."},{"key":"2021021317253200277_j_jpem-2019-0214_ref_008_w2aab3b7c23b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, et al. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab 2008;93:190\u20135.","DOI":"10.1210\/jc.2007-1216"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_009_w2aab3b7c23b1b6b1ab2b1b9Aa","unstructured":"Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab 1999;84:4583\u201390."},{"key":"2021021317253200277_j_jpem-2019-0214_ref_010_w2aab3b7c23b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Arrigo T, De Luca F, Antoniazzi F, Galluzzi F, Segni M, et al. Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty. Eur J Endocrinol 2004;150:533\u20137.","DOI":"10.1530\/eje.0.1500533"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_011_w2aab3b7c23b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"van der Sluis IM, Boot AM, Krenning EP, Drop SL, de Muinck Keizer-Schrama SM. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J Clin Endocrinol Metab 2002;87:506\u201312.","DOI":"10.1210\/jcem.87.2.8202"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_012_w2aab3b7c23b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Wolters B, Lass N, Reinehr T. Treatment with gonadotropin-releasing hormone analogues: different impact on body weight in normal-weight and overweight children. Horm Res Paediatr 2012;78:304\u201311.","DOI":"10.1159\/000346145"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_013_w2aab3b7c23b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Neely EK, Hintz RL, Wilson DM, Lee PA, Gautier T, et al. Normal ranges for immunochemiluminometric gonadotropin assays. J Pediatr 1995;127:40\u20136.","DOI":"10.1016\/S0022-3476(95)70254-7"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_014_w2aab3b7c23b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Neely EK, Wilson DM, Lee PA, Stene M, Hintz RL. Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. J Pediatr 1995;127:47\u201352.","DOI":"10.1016\/S0022-3476(95)70255-5"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_015_w2aab3b7c23b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Carel JC, Lahlou N, Roger M, Chaussain JL. Precocious puberty and statural growth. Hum Reprod Update 2004;10:135\u201347.","DOI":"10.1093\/humupd\/dmh012"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_016_w2aab3b7c23b1b6b1ab2b1c16Aa","unstructured":"Rosenfield RL CD, Radovick S. Puberty and its disorders in a female. In: Sperling MA, editor. Pediatric Endocrinology. 3rd ed. Philadelphia: WB Saunders, 2008:573\u201390."},{"key":"2021021317253200277_j_jpem-2019-0214_ref_017_w2aab3b7c23b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Lee PA, Page JG. Effects of leuprolide in the treatment of central precocious puberty. J Pediatr 1989;114:321\u20134.","DOI":"10.1016\/S0022-3476(89)80806-6"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_018_w2aab3b7c23b1b6b1ab2b1c18Aa","unstructured":"Kappy MS, Ganong CS. Advances in the treatment of precocious puberty. Adv Pediatr 1994;41:223\u201361."},{"key":"2021021317253200277_j_jpem-2019-0214_ref_019_w2aab3b7c23b1b6b1ab2b1c19Aa","unstructured":"Lawson ML, Cohen N. A single sample subcutaneous luteinizing hormone (LH)-releasing hormone (LHRH) stimulation test for monitoring LH suppression in children with central precocious puberty receiving LHRH agonists. J Clin Endocrinol Metab 1999;84:4536\u201340."},{"key":"2021021317253200277_j_jpem-2019-0214_ref_020_w2aab3b7c23b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Fredriks AM, van Buuren S, Wit JM, Verloove-Vanhorick SP. Body index measurements in 1996\u20137 compared with 1980. Arch Dis Child 2000;82:107\u201312.","DOI":"10.1136\/adc.82.2.107"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_021_w2aab3b7c23b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291\u2013303.","DOI":"10.1136\/adc.44.235.291"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_022_w2aab3b7c23b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Milner GR, Levick RK, Kay R. Assessment of bone age: a comparison of the Greulich and Pyle, and the Tanner and Whitehouse methods. Clin Radiol 1986;37:119\u201321.","DOI":"10.1016\/S0009-9260(86)80376-2"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_023_w2aab3b7c23b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, et al. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty. J Clin Endocrinol Metab 1999;84:1973\u20138.","DOI":"10.1210\/jcem.84.6.5647"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_024_w2aab3b7c23b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Arcari AJ, Gryngarten MG, Freire AV, Ballerini MG, Ropelato MG, et al. Body mass index in girls with idiopathic central precocious puberty during and after treatment with GnRH analogues. Int J Pediatr Endocrinol 2016;2016:15.","DOI":"10.1186\/s13633-016-0033-7"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_025_w2aab3b7c23b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Lazar L, Lebenthal Y, Yackobovitch-Gavan M, Shalitin S, de Vries L, et al. Treated and untreated women with idiopathic precocious puberty: BMI evolution, metabolic outcome, and general health between third and fifth decades. J Clin Endocrinol Metab 2015;100:1445\u201351.","DOI":"10.1210\/jc.2014-3748"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_026_w2aab3b7c23b1b6b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Park J, Kim JH. Change in body mass index and insulin resistance after 1-year treatment with gonadotropin-releasing hormone agonists in girls with central precocious puberty. Ann Pediatr Endocrinol Metab 2017;22:27\u201335.","DOI":"10.6065\/apem.2017.22.1.27"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_027_w2aab3b7c23b1b6b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"Yang WJ, Ko KH, Lee KH, Hwang IT, Oh YJ. The different effects of gonadotropin-releasing hormone agonist therapy on body mass index and growth between normal-weight and overweight girls with central precocious puberty. Ann Pediatr Endocrinol Metab 2017;22:49\u201354.","DOI":"10.6065\/apem.2017.22.1.49"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_028_w2aab3b7c23b1b6b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"Muratoglu Sahin N, Ugras Dikmen A, Cetinkaya S, Aycan Z. Subnormal growth velocity and related factors during GnRH analog therapy for idiopathic central precocious puberty. J Clin Res Pediatr Endocrinol 2018;10:239\u201346.","DOI":"10.4274\/jcrpe.0023"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_029_w2aab3b7c23b1b6b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"Vignolo M, Naselli A, Di Battista E, Mostert M, Aicardi G. Growth and development in simple obesity. Eur J Pediatr 1988;147:242\u20134.","DOI":"10.1007\/BF00442687"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_030_w2aab3b7c23b1b6b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"Davison KK, Susman EJ, Birch LL. Percent body fat at age 5 predicts earlier pubertal development among girls at age 9. Pediatrics 2003;111(4 Pt 1):815\u201321.","DOI":"10.1542\/peds.111.4.815"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_031_w2aab3b7c23b1b6b1ab2b1c31Aa","doi-asserted-by":"crossref","unstructured":"He Q, Karlberg J. BMI in childhood and its association with height gain, timing of puberty, and final height. Pediatr Res 2001;49:244\u201351.","DOI":"10.1203\/00006450-200102000-00019"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_032_w2aab3b7c23b1b6b1ab2b1c32Aa","doi-asserted-by":"crossref","unstructured":"Denzer C, Weibel A, Muche R, Karges B, Sorgo W, et al. Pubertal development in obese children and adolescents. Int J Obes 2007;31:1509\u201319.","DOI":"10.1038\/sj.ijo.0803691"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_033_w2aab3b7c23b1b6b1ab2b1c33Aa","doi-asserted-by":"crossref","unstructured":"Reilly JJ, Kelly J. Long-term impact of overweight and obesity in childhood and adolescence on morbidity and premature mortality in adulthood: systematic review. Int J Obes 2011;35:891\u20138.","DOI":"10.1038\/ijo.2010.222"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_034_w2aab3b7c23b1b6b1ab2b1c34Aa","doi-asserted-by":"crossref","unstructured":"Kaya M, Sayan A, Birinci M, Yildiz M, Turkmen K. The obesity prevalence among students between the ages of 5 and 19 in Kutahya. Turk J Med Sci 2014;44:10\u20135.","DOI":"10.3906\/sag-1301-71"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_035_w2aab3b7c23b1b6b1ab2b1c35Aa","doi-asserted-by":"crossref","unstructured":"Yuca SA, Yilmaz C, Cesur Y, Dogan M, Kaya A, et al. Prevalence of overweight and obesity in children and adolescents in eastern Turkey. J Clin Res Pediatr Endocrinol 2010;2:159\u201363.","DOI":"10.4274\/jcrpe.v2i4.159"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_036_w2aab3b7c23b1b6b1ab2b1c36Aa","doi-asserted-by":"crossref","unstructured":"Discigil G, Tekin N, Soylemez A. Obesity in Turkish children and adolescents: prevalence and non-nutritional correlates in an urban sample. Child Care Health Dev 2009;35:153\u20138.","DOI":"10.1111\/j.1365-2214.2008.00919.x"},{"key":"2021021317253200277_j_jpem-2019-0214_ref_037_w2aab3b7c23b1b6b1ab2b1c37Aa","unstructured":"Turkkahraman D, Bircan I, Tosun O, Saka O. Prevalence and risk factors of obesity in school children in Antalya, Turkey. Saudi Med J 2006;27:1028\u201333."},{"key":"2021021317253200277_j_jpem-2019-0214_ref_038_w2aab3b7c23b1b6b1ab2b1c38Aa","doi-asserted-by":"crossref","unstructured":"Pirincci E, Durmus B, Gundogdu C, Acik Y. Prevalence and risk factors of overweight and obesity among urban school children in Elazig city, Eastern Turkey, 2007. Ann Hum Biol 2010;37:44\u201356.","DOI":"10.3109\/03014460903218984"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/jpem\/33\/1\/article-p99.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2019-0214\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2019-0214\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T01:46:05Z","timestamp":1619055965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2019-0214\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,5]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12,5]]},"published-print":{"date-parts":[[2020,1,28]]}},"alternative-id":["10.1515\/jpem-2019-0214"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2019-0214","relation":{},"ISSN":["2191-0251","0334-018X"],"issn-type":[{"value":"2191-0251","type":"electronic"},{"value":"0334-018X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,5]]}}}